News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
266,418 Results
Type
Article (13859)
Company Profile (101)
Press Release (252458)
Multimedia
Podcasts (47)
Webinars (10)
Section
Business (88227)
Career Advice (465)
Deals (15373)
Drug Delivery (67)
Drug Development (36727)
Employer Resources (49)
FDA (6308)
Job Trends (6221)
News (150558)
Policy (14067)
Tag
2024 BioCapital Digital (8)
2024 BioForest Digital (3)
2024 BioForest Standard (1)
2024 BioMidwest Digital (3)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (3)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (7)
2024 Biotech Beach Digital (4)
2024 Biotech Beach Standard (1)
2024 Genetown Digital (3)
2024 Genetown Standard (3)
2024 Lone Star Bio Digital (2)
2024 Pharm Country Digital (2)
2024 Pharm Country Standard (2)
2025 BioForest Digital (2)
2025 Lone Star Bio Digital (4)
2026 BioCapital Standard (1)
2026 Biotech Bay Standard (1)
2026 Pharm Country Standard (1)
Academia (443)
Accelerated approval (2)
Adcomms (6)
Allergies (35)
Alliances (23270)
ALS (37)
Alzheimer's disease (393)
Antibody-drug conjugate (ADC) (42)
Approvals (6348)
Artificial intelligence (110)
Autoimmune disease (9)
Automation (4)
Bankruptcy (149)
Best Places to Work (4388)
BIOSECURE Act (9)
Biosimilars (57)
Biotechnology (40)
Bladder cancer (22)
Brain cancer (16)
Breast cancer (83)
Cancer (646)
Cardiovascular disease (72)
Career advice (408)
Career pathing (12)
CAR-T (24)
Cell therapy (91)
Cervical cancer (4)
Clinical research (31047)
Collaboration (353)
Compensation (155)
Complete response letters (17)
COVID-19 (758)
CRISPR (21)
C-suite (126)
Cystic fibrosis (37)
Data (663)
Denatured (15)
Depression (9)
Diabetes (83)
Diagnostics (1327)
Diversity (2)
Diversity, equity & inclusion (13)
Drug discovery (61)
Drug pricing (66)
Drug shortages (12)
Duchenne muscular dystrophy (37)
Earnings (32296)
Editorial (12)
Employer branding (4)
Employer resources (43)
Events (37654)
Executive appointments (397)
FDA (6741)
Featured Employer (20)
Friedreich's ataxia (2)
Frontotemporal dementia (1)
Funding (215)
Gene editing (39)
Generative AI (9)
Gene therapy (101)
GLP-1 (356)
Government (1301)
Grass and pollen (3)
Guidances (17)
Healthcare (3567)
Huntington's disease (4)
IgA nephropathy (12)
Immunology and inflammation (34)
Indications (14)
Infectious disease (793)
Inflammatory bowel disease (56)
Inflation Reduction Act (6)
Influenza (14)
Intellectual property (48)
Interviews (59)
IPO (5903)
IRA (29)
Job creations (2053)
Job search strategy (373)
Kidney cancer (7)
Labor market (12)
Layoffs (180)
Leadership (3)
Legal (3442)
Liver cancer (19)
Lung cancer (87)
Lymphoma (61)
Machine learning (2)
Management (16)
Manufacturing (161)
MASH (33)
Medical device (1279)
Medtech (1281)
Mergers & acquisitions (9681)
Metabolic disorders (265)
Multiple sclerosis (21)
NASH (14)
Neurodegenerative disease (24)
Neuropsychiatric disorders (8)
Neuroscience (582)
NextGen: Class of 2025 (1588)
Non-profit (595)
Northern California (738)
Now hiring (8)
Obesity (151)
Opinion (119)
Ovarian cancer (22)
Pain (52)
Pancreatic cancer (15)
Parkinson's disease (47)
Partnered (7)
Patents (120)
Patient recruitment (29)
Peanut (10)
People (29004)
Pharmaceutical (64)
Pharmacy benefit managers (11)
Phase I (8093)
Phase II (13131)
Phase III (11775)
Pipeline (463)
Policy (72)
Postmarket research (1404)
Preclinical (3241)
Press Release (25)
Prostate cancer (48)
Psychedelics (8)
Radiopharmaceuticals (120)
Rare diseases (170)
Real estate (2641)
Recruiting (17)
Regulatory (10150)
Reports (14)
Research institute (566)
Resumes & cover letters (55)
Rett syndrome (1)
RNA editing (2)
RSV (8)
Schizophrenia (37)
Series A (37)
Series B (13)
Service/supplier (3)
Sickle cell disease (32)
Southern California (744)
Special edition (6)
Spinal muscular atrophy (79)
Sponsored (6)
Startups (1633)
State (2)
Stomach cancer (3)
Supply chain (32)
Tariffs (30)
The Weekly (30)
United States (7406)
Vaccines (155)
Venture capitalists (14)
Weight loss (100)
Women's health (8)
Worklife (3)
Date
Today (70)
Last 7 days (268)
Last 30 days (931)
Last 365 days (11769)
2025 (3841)
2024 (12517)
2023 (14271)
2022 (19573)
2021 (20123)
2020 (19094)
2019 (14919)
2018 (11751)
2017 (13934)
2016 (13144)
2015 (15495)
2014 (12443)
2013 (10600)
2012 (11409)
2011 (11949)
2010 (10915)
Location
Africa (313)
Alabama (13)
Alaska (1)
Arizona (56)
Arkansas (3)
Asia (20148)
Australia (2617)
California (1779)
Canada (928)
China (247)
Colorado (71)
Connecticut (70)
Delaware (60)
Europe (39685)
Florida (337)
Georgia (38)
Idaho (9)
Illinois (200)
India (16)
Indiana (136)
Iowa (1)
Japan (94)
Kansas (58)
Kentucky (12)
Louisiana (1)
Maine (2)
Maryland (263)
Massachusetts (1520)
Michigan (30)
Minnesota (95)
Missouri (23)
Montana (8)
Nebraska (6)
Nevada (8)
New Hampshire (6)
New Jersey (780)
New Mexico (7)
New York (528)
North Carolina (402)
North Dakota (2)
Northern California (738)
Ohio (51)
Oklahoma (4)
Oregon (16)
Pennsylvania (458)
Puerto Rico (8)
Rhode Island (10)
South America (502)
South Carolina (2)
Southern California (744)
Tennessee (34)
Texas (235)
Utah (34)
Virginia (76)
Washington D.C. (31)
Washington State (123)
Wisconsin (17)
266,418 Results for "servier pharmaceuticals".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Deals
Servier Nabs Solid Tumor Asset in up to $780M Deal With Black Diamond
The French pharma is getting Black Diamond’s de-prioritized molecule for non-small cell lung cancers with specific mutations whose development had been paused to save money.
March 19, 2025
·
2 min read
·
Dan Samorodnitsky
Approvals
Servier Gets FDA Approval for First Targeted Therapy for Grade 2 IDH-Mutant Glioma
Servier Pharmaceuticals’ vorasidenib on Tuesday secured the FDA’s green light for the treatment of patients with grade 2 gliomas carrying mutations in the IDH gene.
August 7, 2024
·
2 min read
·
Tristan Manalac
Press Releases
Servier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933, A Targeted Oncology Therapy
March 19, 2025
·
6 min read
Genetown
Servier Initiates Critical Dialogue on AYA Cancer Survivorship at ASCO 2024
Servier, a leader in oncology committed to delivering transformative therapies to patients, announced that it will underwrite a panel hosted by The Atlantic.
May 30, 2024
·
3 min read
Genetown
Servier Highlights Commitment to Improving Cancer Outcomes at ASCO 2024
Servier will showcase data from across its oncology portfolio at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, May 31-June 4.
May 23, 2024
·
3 min read
Genetown
Servier Data Presented at AACR Underscores Unwavering Dedication to Advancing Oncology R&D
Servier, a science driven company focused on developing transformative precision therapies for patients, is poised to unveil promising preliminary data at the American Association for Cancer Research Annual Meeting 2024.
April 8, 2024
·
4 min read
Press Releases
Servier to Present Data on IDH-mutant Glioma at the 2024 Society for Neuro-Oncology (SNO) Congress
November 13, 2024
·
3 min read
Press Releases
Servier Announces Expansion of its Tibsovo (ivosidenib) Development Program Investigating its Safety and Efficacy in Patients Living with IDH1-Mutated Cancers in Both Hematological Malignancies and Solid Tumors
January 10, 2025
·
12 min read
Servier partners with Owkin with the aim of discovering and developing AI-driven precision therapeutics
Servier, a global independent pharmaceutical group, and Owkin, a French American biotech focused on applying artificial intelligence (AI) to drug discovery,
October 17, 2023
·
8 min read
Policy
Servier Receives Regulatory Filing Acceptances from FDA and EMA for Vorasidenib in the Treatment of IDH-Mutant Diffuse Glioma
Servier today announced the FDA filing acceptance and priority review for a New Drug Application (NDA) for vorasidenib, as well as the EMA granting accelerated assessment for the vorasidenib Marketing Authorization Application (MAA).
February 21, 2024
·
12 min read
1 of 26,642
Next
